pimitespib   Click here for help

GtoPdb Ligand ID: 12284

Synonyms: compound 16e [PMID: 30525599] | Jeselhy® | TAS-116 | TAS116
Compound class: Synthetic organic
Comment: Pimitespib (TAS-116) is an orally bioavailable heat shock protein 90 α/β (HSP90α/β) inhibitor [6], that promotes proteasomal degradation of oncogenic HSP90 client proteins, and induces apoptosis of cells that overexpress (HSP90α/β). Reported to bind at the N-terminal ATP binding site of the target proteins [6]. Pimitespib was developed for potential antineoplastic activity [1,3-5].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 108.4
Molecular weight 454.22
XLogP 3.87
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCc1cc(ccc1n1nc(c2c1nccc2n1cnc(c1)c1cnn(c1)C)C(C)C)C(=O)N
Isomeric SMILES CCc1c(ccc(c1)C(=O)N)n1c2nccc(c2c(n1)C(C)C)n1cc(nc1)c1cn(nc1)C
InChI InChI=1S/C25H26N8O/c1-5-16-10-17(24(26)34)6-7-20(16)33-25-22(23(30-33)15(2)3)21(8-9-27-25)32-13-19(28-14-32)18-11-29-31(4)12-18/h6-15H,5H2,1-4H3,(H2,26,34)
InChI Key NVVPMZUGELHVMH-UHFFFAOYSA-N
References
1. Doi T, Kurokawa Y, Sawaki A, Komatsu Y, Ozaka M, Takahashi T, Naito Y, Ohkubo S, Nishida T. (2019)
Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
Eur J Cancer, 121: 29-39. [PMID:31536852]
2. Hoy SM. (2022)
Pimitespib: First Approval.
Drugs, 82 (13): 1413-1418. [PMID:35986838]
3. Kawazoe A, Itahashi K, Yamamoto N, Kotani D, Kuboki Y, Taniguchi H, Harano K, Naito Y, Suzuki M, Fukutani M et al.. (2021)
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
Clin Cancer Res, 27 (24): 6709-6715. [PMID:34593531]
4. Ohkubo S, Kodama Y, Muraoka H, Hitotsumachi H, Yoshimura C, Kitade M, Hashimoto A, Ito K, Gomori A, Takahashi K et al.. (2015)
TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.
Mol Cancer Ther, 14 (1): 14-22. [PMID:25416789]
5. Suzuki R, Hideshima T, Mimura N, Minami J, Ohguchi H, Kikuchi S, Yoshida Y, Gorgun G, Cirstea D, Cottini F et al.. (2015)
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Leukemia, 29 (2): 510-4. [PMID:25306900]
6. Uno T, Kawai Y, Yamashita S, Oshiumi H, Yoshimura C, Mizutani T, Suzuki T, Chong KT, Shigeno K, Ohkubo M et al.. (2019)
Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.
J Med Chem, 62 (2): 531-551. [PMID:30525599]